TheraRadar
← Back
Data updated: Mar 29, 2026

IPHARM

OncologyMetabolicCardiovascular
Pharma

IPHARM is a pharmaceutical company focused on Oncology, Metabolic, Cardiovascular.

-
Since
1
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 61%
0 drugs Phase 3: 43 Phase 2: 78 Phase 1: 164
Metabolic 15%
0 drugs Phase 3: 20 Phase 2: 8 Phase 1: 26
Cardiovascular 9%
0 drugs Phase 3: 13 Phase 2: 7 Phase 1: 8
Respiratory 8%
0 drugs Phase 3: 7 Phase 2: 13 Phase 1: 13
Gastroenterology 7%
0 drugs Phase 3: 5 Phase 2: 11 Phase 1: 11

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Cardiovascular
BRACCO specialty
Cardiovascular, Oncology, Metabolic, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Metabolic